학술논문

Risk stratification in differentiated thyroid cancer with RAI-avid lung metastases
Document Type
article
Source
Endocrine Connections, Vol 10, Iss 8, Pp 825-833 (2021)
Subject
differentiated thyroid carcinoma
metastatic lung tumor
radioactive iodine therapy
prognostic factor
neutrophil-to-lymphocyte ratio
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Language
English
ISSN
2049-3614
Abstract
Objective: Radioactive iodine (RAI) therapy is effective for differentiated thyroid cancer (DTC) patients with lung metastasis. However, some patients have a poor prognosis despite the RAI accumulation. The utility of inflammatory biomar kers, including neutrophil-to-lymphocyte ratio (NLR), has been reported as a pr ognostic factor for many carcinomas. This study aimed to investigate the risk factors related to DTC patient survival with RAI-avid lung metastasis and to attempt risk stra tification. Design and methods: This retrospective study included 123 patients with RAI-accumulating lung metastatic DTC. The cause-specific survival (C SS) rate from the time of detection of lung metastasis was tested using the Kaplan–Meier log-rank test, and the multivariate analysis was calculated using the Cox proportional hazards model. NLR was retrospectively calculated using the blood sample collected bef ore initial RAI treatment. The NLR cutoff value was 2.6 on the ROC curve. Results: Age ≥ 55 years at the time of operative treatment, follicular carcinoma, lung metastasis tumor ≥ 10 mm in diameter, age ≥ 55 years at the time of detection of lung metastasis, age ≥ 55 years at the time of RAI treatment, and NLR ≥ 2.6 at the initial RAI treatment were predictive of decreased CSS. Multivariate analys is identified that the independent prognostic factors were lung metastatic tumor ≥ 10 mm in diameter and NLR ≥ 2.6. Patients in the high-risk group with both factors had sig nificantly lower CSS rates than those in the low- and intermediate-risk groups with one or none of these factors. Conclusions: The high-risk group patients had significantly poorer survival, and these patients could be considered as future candidates for tyrosine kinase inhibitor therapy.